Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 19 , ISSUE 1 ( 2015 ) > List of Articles

RESEARCH ARTICLE

The comparison of extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous pantoprazole on the gastric pH of critically ill-patients

Yasamin Dabiri, Fanak Fahimi, Hamidreza Jamaati, Seyed Mohammad Hashemian

Keywords : Gastrointestinal bleeding, omeprazole, pantoprazole, stress-related mucosal disease, suspension

Citation Information : Dabiri Y, Fahimi F, Jamaati H, Hashemian SM. The comparison of extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous pantoprazole on the gastric pH of critically ill-patients. Indian J Crit Care Med 2015; 19 (1):21-26.

DOI: 10.4103/0972-5229.148635

License: CC BY-ND 3.0

Published Online: 00-01-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: Stress-related mucosal disease occurs in many critically ill-patients within 24 h of admission. Proton pump inhibitor therapy has been documented to produce more potent inhibition of gastric acid secretion than histamine 2 receptor antagonists. This study aimed to compare extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous (IV) pantoprazole on the gastric pH in intensive care unit patients. Materials and Methods: This was a randomized single-blind-study. Patients of ≥ 16 years of age with a nasogastric tube, who required mechanical ventilation for ≥ 48 h, were eligible for inclusion. The excluded patients were those with active gastrointestinal bleeding, known allergy to omeprazole and pantoprazole and those intolerant to the nasogastric tube. Fifty-six patients were randomized to treatment with omeprazole suspension 2 mg/ml (40 mg every day), pantoprazole suspension 2 mg/ml (40 mg every day) and IV pantoprazole (40 mg every day) for up to 14 days. Gastric aspirates were sampled before and 1-2.5 h after the drug administration for the pH measurement using an external pH meter. Data were analyzed using SPSS (version 21.0). Results: In this study, 56 critically ill-patients (39 male, 17 female, mean age: 61.5 ± 15.65 years) were followed for the control of the gastric pH. On each of the 14 trial days the mean of the gastric pH alteration was significantly higher in omeprazole and pantoprazole suspension-treated patients than in IV pantoprazole-treated patients (P < 0.001). Conclusion: Omeprazole and pantoprazole oral suspension are more effective than IV pantoprazole in increasing the gastric pH.


PDF Share
  1. Metz DC. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000;62:73-81.
  2. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: Rationale for the therapeutic benefits of acid suppression. Crit Care Med 2002;30:S351-5.
  3. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5:368-75.
  4. Steinberg KP. Stress-related mucosal disease in the critically ill patient: Risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med 2002;30:S362-4.
  5. Yasue N, Guth PH. Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology 1988;94:1135-43.
  6. Kamada T, Sato N, Kawano S, Fusamoto H, Abe H. Gastric mucosal hemodynamics after thermal or head injury. A clinical application of reflectance spectrophotometry. Gastroenterology 1982;83:535-40.
  7. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-96.
  8. Phillips JO, Metzler MH, Palmieri MT, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800.
  9. Wurzer H, Schutze K, Bethke T, Fischer R, Luhmann R, Riesenhuber C. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology 1999;46:1809-15.
  10. Metz DC, Pratha V, Martin P, Paul J, Maton PN, Lew E, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000;95:626-33.
  11. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000;118:696-704.
  12. Bardhan KD. Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (Barc) 1999;35:773-808.
  13. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82.
  14. Velayati AA, Mehrabi Y, Radmand G, Maboudi AA, Jamaati HR, Shahbazi A, et al. Modification of Acute Physiology and Chronic Health Evaluation II score through recalibration of risk prediction model in critical care patients of a respiratory disease referral center. Int J Crit Illn Inj Sci 2013;3:40-5.
  15. Feldman M. Pharmacology of untiulcer medications. Available from: http://www.uptodate.com/clinicians/content/topic.doptopickey=Ym-odubHEMPOk. [Last accessed on 2013 Sep 8].
  16. Jew RK, editor. Extemporaneous Formulations for Pediatric, Geriatric, and Special Needs Patients. 2 nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2010.
  17. Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005;33:760-5.
  18. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-9.
  19. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998;44:527-33.
  20. Hernández C, el-Ebiary M, Gonzalez J, de la Bellacasa JP, Montón C, Torres A. Relationship between ventilator-associated pneumonia and intramucosal gastric pHi: A case-control study. J Crit Care 1996;11:122-8.
  21. Li HY, He LX, Hu BJ, Wang BQ, Zhang XY, Chen XH, et al. The impact of gastric colonization on the pathogenesis of ventilator-associated pneumonia. Zhonghua Nei Ke Za Zhi 2004;43:112-6.
  22. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998;338:791-7.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.